임상시험 트래커
추적 기업 30곳의 임상 6,982건 (국내 전체 이력 · 글로벌 진행 중). 출처: ClinicalTrials.gov
기업
47건 표시
- 1상모집 중· HealthyA Study to Assess Nipocalimab Concentrations in Breast Milk of Healthy Lactating Women
리드: 얀센(J&J)
- 1상모집 중· Hematologic NeoplasmsA Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
리드: 얀센(J&J)
- 1상모집 중· Lymphoma, Non-HodgkinA Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies
리드: 얀센(J&J)
- 1상모집 중· Prostatic NeoplasmsA Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer
리드: 얀센(J&J)
- 1상모집 중· Relapsed Refractory Multiple Myeloma (RRMM)Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma
협력: 얀센(J&J)
- 1상모집 중· Acute Lymphoblastic LeukemiaA Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute Leukemia
리드: 얀센(J&J)
- 1상모집 중· Advanced-stage Solid TumorsA Study of JNJ-89862175 for Treatment of Advanced Solid Tumors
리드: 얀센(J&J)
- 1상모집 중· Multiple MyelomaTalquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma
협력: 얀센(J&J)
- 1상모집 중· Colorectal NeoplasmsA Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumors
리드: 얀센(J&J)
- 1상모집 중· Prostatic NeoplasmsA Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer
리드: 얀센(J&J)
- 1상모집 중· Leukemia, Myeloid, AcuteA Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms
리드: 얀센(J&J)
- 1상모집 중· Solid TumorsORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC
협력: 얀센(J&J)
- 1상모집 중단 (진행 중)· Leukemia, Myeloid, AcuteA Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms
리드: 얀센(J&J)
- 1상초청 등록· Leukemia, Myeloid, AcuteA Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
리드: 얀센(J&J)
- 1상모집 중단 (진행 중)· Relapsed or Refractory Multiple MyelomaA Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma
리드: 얀센(J&J)
- 1상모집 중단 (진행 중)· Lymphoma, Non-HodgkinA Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R B-Cell NHL)
리드: 얀센(J&J)
- 1상모집 중· Colorectal NeoplasmsA Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers
리드: 얀센(J&J)
- 1상모집 중단 (진행 중)· Multiple MyelomaA Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
리드: 얀센(J&J)
- 1상모집 중단 (진행 중)· Lymphoma, Non-HodgkinA Study of JNJ-88998377 for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
리드: 얀센(J&J)
- 1상모집 중· Human Immunodeficiency VirusEvaluation of Safety and Immunogenicity of Ad26.Mos4.HIV and CH505 TF chTrimer Combination in Healthy Adults
협력: 얀센(J&J)
- 1상모집 중단 (진행 중)· Lymphoma, Non-HodgkinA Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer
리드: 얀센(J&J)
- 1상모집 중단 (진행 중)· Relapsed or Refractory B Cell Non-Hodgkin LymphomaA Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)
리드: 얀센(J&J)
- 1상모집 중· Prostatic NeoplasmsA Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
리드: 얀센(J&J)
- 1상모집 중· Metastatic Castration-resistant Prostate NeoplasmsA Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
리드: 얀센(J&J)
- 1상모집 중· Relapsed or Refractory Multiple MyelomaA Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
리드: 얀센(J&J)
- 1상모집 중단 (진행 중)· Leukemia, Myeloid, AcuteA Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies
리드: 얀센(J&J)
- 1상모집 중단 (진행 중)· Lymphoma, Non-HodgkinA Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
리드: 얀센(J&J)
- 1상모집 중단 (진행 중)· Relapsed/ Refractory Multiple MyelomaA Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma
리드: 얀센(J&J)
- 1상모집 중단 (진행 중)· Multiple MyelomaA Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma
리드: 얀센(J&J)
- 1상모집 중단 (진행 중)· Prostatic NeoplasmsA Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer
리드: 얀센(J&J)
- 1상모집 중단 (진행 중)· Metastatic Prostate CancerARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer
리드: 얀센(J&J)
- 1상모집 중단 (진행 중)· Multiple MyelomaA Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma
리드: 얀센(J&J)
- 1상모집 중단 (진행 중)· Prostatic NeoplasmsA Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer
리드: 얀센(J&J)
- 1상모집 중단 (진행 중)· Prostatic NeoplasmsA Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer
리드: 얀센(J&J)
- 1상모집 중단 (진행 중)· NeoplasmsA Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies
리드: 얀센(J&J)
- 1상모집 중단 (진행 중)· Leukemia, Myeloid, AcuteCusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia
협력: 얀센(J&J)
- 1상모집 중단 (진행 중)· Carcinoma, Non-Small-Cell LungA Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer
리드: 얀센(J&J)
- 1상모집 중단 (진행 중)· Prostatic NeoplasmsA Study of Androgen Receptor (AR) Antagonist Apalutamide in Chinese Participants With Metastatic Castration-Resistant Prostate Cancer
리드: 얀센(J&J)
- 1상모집 중단 (진행 중)· Hematological MalignanciesDose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
리드: 얀센(J&J)
- 1상모집 중단 (진행 중)· Hematological MalignanciesDose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma
리드: 얀센(J&J)
- 1상모집 중단 (진행 중)· Non-Small-Cell Lung CancerStudy of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer
리드: 얀센(J&J)
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.